《美股業績》禮來(LLY.US)去年糖尿病藥物銷售遜 今年全年盈測勝預期
禮來(LLY.US)截至去年12月底止第四純盈利上升12%至19.37億美元,收入為73億美元,低於市場預期的73.3億美元,但乳腺癌藥物Verzenio表現理想,銷售增加一倍至8.08億美元,超出分析師預期逾1億美元,不過備受關注的新型2型糖尿病藥物Mounjaro以及另一款糖尿病藥物Trulicity的銷售皆未達預期。
禮來預計今年調整後每股盈利為8.35至8.55美元,高於分析師預期的8.28美元,因公司稅率可能低於原先預期。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.